Survival in Childhood Malignancies: Assessment of the Influence of Age, Sex, and Tumor Type, With Emphasis on “Long-Term Survivors”2

2018 ◽  
Vol 27 (5) ◽  
pp. 1891-1899
Author(s):  
Deniz Çetiner ◽  
Sedat Çetiner ◽  
Ahu Uraz ◽  
Gökhan H. Alpaslan ◽  
Cansu Alpaslan ◽  
...  

2007 ◽  
Vol 25 (12) ◽  
pp. 1532-1538 ◽  
Author(s):  
E. Brannon Morris ◽  
Amar Gajjar ◽  
James O. Okuma ◽  
Yutaka Yasui ◽  
Dana Wallace ◽  
...  

Purpose To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor. Patients and Methods The study population comprised 643 pediatric patients with primary CNS tumor treated at St Jude Children's Research Hospital (Memphis, TN) from 1985 to 2000 who survived ≥ 5 years from diagnosis. Patients were classified according to primary tumor type, location of tumor, and survival. Cause of death was obtained from the medical record and categorized as progression, malignant transformation, second malignancy, medical complication, or external cause. Results Overall survival estimates for patients who survived at least 5 years postdiagnosis was 91.3% ± 2% and 86% ± 3% at 10 and 15 years postdiagnosis, respectively. A significant difference in the survival rates according to original tumor type (P = .001) was seen. Sixty-six (10%) of 643 patients experienced late mortality: 38 patients (58%) died of progressive disease while 14 patients (21%) died of second malignant tumor. Twelve patients (18%), predominantly with diencephalic tumor location, died of a specific medical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and/or sepsis (n = 7), respiratory failure (n = 1), or shunt malfunction (n = 1). Conclusion Late mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most influenced by the initial tumor histopathology. Progressive disease remains the most common cause of death within the first decade of diagnosis. Teenage patients requiring treatment for panhypopituitarism may be especially vulnerable and deserve significant medical surveillance.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13025-e13025 ◽  
Author(s):  
Kyungsuk Jung ◽  
Marijo Bilusic ◽  
Jianming Pei ◽  
Michael Slifker ◽  
Yan Zhou ◽  
...  

e13025 Background: A few patients with metastatic cancer survive exceptionally longer than others under the same treatment. We hypothesized that there is a specific biologic signature in genetic profiles of long-term survivors that plays a key role in sensitivity to systemic treatment. Methods: Twenty-six patients with metastatic cancer treated at Fox Chase cancer center with exceptional response were included in the study. Exceptional response was defined as complete response > 1 year or stable disease/partial response > 2 years at any time during the disease course. Archived tumor specimens of 16 patients were sequenced and analyzed using Ambry Genetics 142 gene panel. In addition, genes expressions in tumor tissues from 23 exceptional responders and 23 matched controls (age, sex and tumor type) were analyzed using two NanoString nCounter PanCancer panels (Pathway and Immune Profiling). Results: See Table. Conclusions: Multiple common mutations of NOTCH2, NF1, FANCD2, PIK3CB and EPHA5 were found in tumors that responded exceptionally well to treatments. Additionally, certain genes were significantly over-expressed or under-expressed in these tumors compared to matched controls. Underlying mechanisms that these genetic alterations foster, leading to susceptibility to treatment and prolonged patient survival, should be further studied. [Table: see text]


1982 ◽  
Vol 6 (1) ◽  
pp. 223
Author(s):  
J. C. Allen ◽  
M. D. F. Deck ◽  
J. Howieson ◽  
M. Brown

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii381-iii381
Author(s):  
Martin Harutyunyan ◽  
Lilit Sargsyan ◽  
Samvel Iskanyan ◽  
Lusine Hakobyan ◽  
Ruzanna Papyan ◽  
...  

Abstract BACKGROUND Pediatric CNS tumors are the most common solid childhood malignancies with many challenges facing optimal outcome due to multimodality complex therapies, abandonment, and long-term morbidity. In our three-decades young, country the field of neuro-oncology is in its infancy. MATERIALS: The aim of our study is to assess incidence, epidemiology and treatment outcomes of children diagnosed and treated with CNS tumors within the last 10 years (2009–2019) in the Chemotherapy Clinic of “Muratsan” Hospital Complex of Yerevan State Medical University. RESULTS During these periods 20 patients with CNS tumors were treated in our clinic. 13 patients (65%) were diagnosed with medulloblastoma (2 patients were infants), two patients (10%) with optic pathway glioma, and 5 patients each with pilocytic astrocytoma, ATRT, ETANTR, DIPG, and glioblastoma. Five patients (3 patients with medulloblastoma, 1 patient with pilocytic astrocytoma, 1 patient with ATRT) had metastatic disease at the time of diagnosis. Seventeen patients (80%) had undergone surgery, 8 patients with medulloblastoma received chemo-RT with vincristine. Median follow up time was 15.5 months (range 5–94). Twelve patients (60%) are alive without evidence of disease. 5 patients had disease progression and three patients relapsed. From them, 3 patients died. Long-term survivors are mainly standard risk medulloblastoma patients. All medulloblastoma patients were treated according to HIT-MED guidelines. CONCLUSION Here we report about the pediatric brain tumors of one of the main pediatric oncology units in Armenia for a period of 10 years. The numbers are quite small for firm conclusions, but it shows the emerging need for further research.


1981 ◽  
Vol 9 (2) ◽  
pp. 109-117 ◽  
Author(s):  
Jeffrey C. Allen ◽  
Michael D. F. Deck ◽  
John Howieson ◽  
Mark Brown

Sign in / Sign up

Export Citation Format

Share Document